US20080287758A1 - Illuminator probe with memory device and method - Google Patents

Abstract

An improved medical illuminator (103) with memory chip (241). The memory element retains information useful in the operation of the illuminator, such as probe identification, probe serial number, use history, calibration details, or other information. Further, the illuminator with information chip can be incorporated into a medical probe or device, such as a pulse oximeter system or probe, as well as to be used in surgical devices or other equipment that require illumination. A method of use is also provided.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
• This application is a continuation-in-part of U.S. patent application Ser. No. 11/451,681 filed on Jun. 12, 2006, relating to the detection of local tissue ischemia, which is a continuation-in-part of U.S. patent application Ser. No. 10/651,541 filed on Aug. 29, 2003, now U.S. Pat. No. 7,062,306, which is a continuation of U.S. patent application Ser. No. 10/119,998 filed on Apr. 9, 2002, now U.S. Pat. No. 6,711,426, the disclosures of all of which are incorporated in full by reference.
FIELD OF THE INVENTION
• The present invention relates to devices and methods for providing, simultaneously or near-simultaneously, spectroscopic analysis from more than one somatic site, and more particularly relates to the determination of a difference-weighted analysis wherein the near-simultaneous determination of two (or more) spectroscopically-determined somatic oxygenation saturation values is performed in a manner allowing for the direct and near-simultaneous comparison of these two (or more) somatic saturation values, by direct mutual inspection or computational means, in order to provide synergistic and added medical value above that provided by each individual value considered separately. In another aspect, the present invention provides real-time spectroscopic analysis of in-vivo tissue perfusion from more than one somatic site that is sensitive to local tissue ischemia and insensitive to regional arterial and venous oxygenation.
BACKGROUND OF THE INVENTION
• Ischemia, defined as a reduction in blood flow, can be due to local causes (e.g., due to vascular occlusion or increased metabolism such as a tumor), global causes (e.g., due to body-wide reduced blood flow from reduced cardiac output), or both. However, discriminating the source of changes in tissue oxygenation can be difficult, considering values at each site individually.
• Collecting spectroscopic values from two different sites (e.g., organ versus organ, or two sites within the same organ), and considering or analyzing these together as a difference-weighted measure, can add medical value. For example, a growing difference between a stable and normal cheek tissue oximetry, and a falling colon tissue oximetry, points to a colon-centered pathology rather than to a global cause such as impending cardiac failure. Similarly, a widening difference-weighted measurement between a pulse and tissue oximeter (estimates of arterial and venous saturation, respectively), helps pinpoint the source of the change as cardiovascular pathology, rather than increasing pulmonary failure. Last, a widening spatial gradient, such as a difference-weighted value between a pair of sensors that is scanned over a single breast, reduces the noise from organ-wide regional gradients and highlights local inhomogeneities associated with tumors such as breast cancer. Each of these three exemplary difference-weighted values add medical value above what the absolute values, considered alone and separately, would merit.
• The noninvasive spectroscopic monitoring of hemoglobin saturation in vivo is known in the art. The great majority of such known devices and methods monitor only at one site (U.S. Pat. No. 6,662,033, WO/2003/003914); such devices do not allow for mutual or computational determination of a difference-weighted value. A few devices and methods in the art teach monitoring at more than one sites. For example, U.S. Pat. No. 6,615,065 describes dual monitoring of the brain, wherein the two sensors are applied to a head of the test subject, taking advantage of the unique hemispheric and non-somatic structure of the brain, to monitor two mutually separate regions within a brain of the test subject, with the two values being simultaneously displayed to allow a user to observationally and mutually compare the two. No computational comparison is taught. Further, the '065 patent teaches that it is the unique, hemispheric structure of the brain that allows the device of '065 to operate, and thus the device would not be suitable for somatic monitoring. In contrast, clinicians recognize that the non-brain (the “somatic”) regional of the body constitute an advantageous early warning system not present in the brain, and are some of the first key tissues to be shut down by the body during impending failure of oxygen delivery to tissue. Similarly, U.S. Patent Application Publication no. 2006/0105319 describes the measuring of two values, arterial and venous. However, again no computational comparison is taught, and one of these values is determined through invasive blood sample, not from spectrophotometric measurement of tissue itself.
• All of the above devices are limited to being single measures of oxygenation, are limited or optimized by design or omission to non-somatic tissue, and/or do not allow direct and near-simultaneous mutual comparison or computational processing of at least two somatic values obtained by spectrophotometric measures.
• None of the prior devices or methods allow for a difference-weighted spectroscopy that facilitates simultaneous or near-simultaneous comparison of spectroscopic values from two somatic regions or sites by inspection or computation. Such a system has not been previously described, nor successfully commercialized. Thus, further developments are needed.
SUMMARY AND OBJECTS OF THE INVENTION
• The inventors have discovered that certain diseases (vascular ischemia, cancer) are frequently localized, and by comparing at least two somatic values—either multiple sites or times—within the body, resulting in a more sensitive detection of such local conditions.
• A salient feature of the present invention is that the detection and treatment of diseases such as somatic ischemia or cancer is aided by use of at least two measurements—either by multiple somatic sensors monitoring at least two nearby or distant regions or by dual measurements made by a single sensor over space or time—allowing a direct comparison of these different spectroscopic values by mutual inspection or computation.
• In one aspect, the present invention provides a somatic monitoring apparatus comprising: a first and second sensor, each configured to generate, based upon light produced and/or detected by each sensor, first and second somatic output signals that are a function of each somatic target site, and a difference unit for comparing said first and second signals, and for generating a difference-weighted output signal based upon this comparison.
• In other embodiments, this dual-sensor somatic tissue ischemia monitoring apparatus generates an output signal that is a function of the presence or degree of local tissue ischemia or cancer at a first and second target site, with a display unit configured to display or allow near or substantially simultaneous comparison of said signals at the two target sites. This can be expanded to N sensors, with comparisons of a first through Nth output signals via a difference unit configured to compare at least two of said first through Nth somatic signals, and to generate a difference-weighted output signal based upon said comparison.
• In yet another aspect, the difference measurement can be generated using a single sensor moved through space (allowing comparison of two sites with one detector), or used over time (such as reporting changes with time), or even measuring both arterial and tissue oximetry measurements using one probe (allow arteriovenous differences to be detected).
• In embodiments of the present invention, we provide both apparatus and methods for the dual, N, and signal sensor approaches. In one embodiment of the invention there is provided a device with dual somatic spectroscopic monitoring sites, including two solid state broadband light sources and sensors for generating, delivering, and detecting light from at least two target sites, for the purpose of allowing a direct comparison of the spectroscopic values by mutual inspection or computation, thereby adding medical value. In another example, the system uses dual phosphor-coated white LED's to produce continuous, broadband, visible light from 400 nm to 700 nm at two somatic sites. Scattered light returning from each target is detected by a wavelength-sensitive detector, and two signals, one from each site, is generated using this wavelength-sensitive information via spectroscopic analysis. The values are displayed or computed in a manner to allow direct comparison of the spectroscopic values by mutual inspection or computation. Systems incorporating the difference-weighted somatic spectroscopic system and medical methods of use are described.
• Some embodiments the present invention further provide a device for detecting local ischemia in a tissue at one or more tissue sites, characterized in that the device is configured such that wavelengths of light are selectively emitted, and the selective wavelengths are substantially transmitted through capillaries in tissue while being substantially absorbed by arterial and venous vessels in the tissue.
• As will be understood by the detailed description below, the somatic monitoring apparatus provides one or more advantages. For example, by way of illustration and in no way limiting the invention, one advantage is that the system and method may be constructed to detect ischemia, cancer, or changes in perfusion.
• Another exemplary advantage is that a physician or surgeon can obtain improved real-time feedback regarding local tissue ischemia, cancer, or perfusion in high-risk patients, and to respond accordingly.
• Another exemplary advantage is that ischemia (low delivery of oxygen to tissues) can be differentiated from pulmonary-induced hypoxemia (low arterial saturation).
• Yet another exemplary advantage is that local changes in oximetry (vascular disease) can be differentiated from mixed or global changes (low cardiac output).
• Another advantage is that the detector of the present invention may be actively coupled to a therapeutic device, such as a pacemaker, to provide feedback to the pacing function, or passively coupled to a therapeutic device, such as applied to a stent to monitor stent performance over time, based upon the detection and degree of local ischemia. Ischemia sensing may be used to enable detection of many types of disease, such as tissue rejection, tissue infection, vessel leakage, vessel occlusion, and the like, many of which produce ischemia as an aspect of the disease.
• The breadth of uses and advantages of the present invention are best understood by example, and by a detailed explanation of the workings of a constructed apparatus, now in tested in human subjects. These and other advantages of the invention will become apparent when viewed in light of the accompanying drawings, examples, and detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
• The breadth of uses and advantages of the present invention are best understood by example, and by a detailed explanation of the workings of a constructed device. These and other advantages of the present invention will become apparent upon consideration of the following detailed description, taken in conjunction with the accompanying drawings, in which like reference characters refer to like parts throughout, and in which:
• FIG. 1 a schematic diagram of a difference-weighted spectroscopy system incorporating a white LED and constructed in accordance with embodiments of the present invention;
• FIG. 2 shows a medical monitor system constructed in accordance with embodiments the present invention;
• FIG. 3A shows a pulsatile broadband signal intensity using a single probe monitor constructed to monitor both arterial and capillary saturation in accordance with some embodiments of the present invention;
• FIG. 3B shows a peak systolic and trough diastolic pulse oximetry signal measured using a single probe difference monitor constructed in accordance with some embodiments of the present invention; and
• FIG. 4 shows an exemplary sensor probe having one light and two (dual) monitoring fibers for monitoring two closely located sites, in this case located at different depths in a tissue, according to some embodiments of the present invention.
DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTIONDefinitions
• For the purposes of this invention, the following definitions are provided for illustration purposes. These definitions are not intended to limit the scope of the invention:
• Head or Cranial: Associated with the Head or Skull, respectively, as opposed to the body tissue (c.f., Somatic, below). Stedman's Medical Dictionary, 27th edition, states that cranial is “Relating to the cranium or head.” Blood perfusion to the brain and head, via the carotid supply, can be very different than to somatic tissues, such as liver, intestine, heart, kidney, and others.
• Somatic: Tissue in the body and central organs, as opposed to the brain (c.f., brain). Stedman's Medical Dictionary, 27th edition, states that this is “[r]elating to the soma or trunk”. Organs within the body are considered somatic tissues, and include the liver, spleen, intestine, heart, kidney, muscle, and pancreas. Oxygenation and measures in somatic tissues are central to monitoring for sufficiency of oxygen delivery to tissue in the body as a whole.
• Ischemia: A condition in which the perfusion of a tissue is locally inadequate to meet its metabolic needs. Ischemia is distinguished from low blood flow per se in that low blood flow alone does not guarantee ischemia (such as during tissue cooling on which flow can be low without significant ischemia), nor does high flow rule out or prevent ischemia (such as during sepsis or when the blood delivered does not contain adequate oxygen). Ischemia is a co-existing condition in many different types of illnesses, including infection (sepsis), tissue rejection (host vs. graft disease), heart attack (myocardial ischemia), stroke (cerebral ischemia), acute or chronic organ failure, diabetic peripheral vascular disease, and other conditions.
• Perfusion: The flow of blood or other perfusate per unit volume of tissue, as in ventilation/perfusion ratio. Reduction in perfusion is a major clinical problem, and it is associated with, but not equivalent to, ischemia.
• Difference-Weighted: A measurement that is formed from the direct or indirect comparison of two or more oxygenation values, such as somatic venous saturation at organ A to somatic venous saturation of organ B. Another difference measurement is the difference between arterial and venous saturation such as described in detail in co-pending U.S. patent application Ser. No. 11/451,681. Another difference measure is the comparison of a measured value to a baseline or historical value.
• Spectroscopy. Measurement of material, including tissue, using light. Such measures can involve a spectrum composed of only a few wavelengths, such as two discrete wavelengths, or can involve a spectrum recorded over a range using a broadband light source, and a wavelength-resolved detector.
• One embodiment of the device will now be described. This device has been built in prototype form, tested in the laboratory under experimental conditions, and tested on animals under Animal Study Review Board approval, as shown in some of the data which follow the initial description of one embodiment of the system.
• A cut-away schematic showing the interior of spectroscopic device orapparatus101 according to embodiments of the present invention is shown inFIG. 1.Device101 is preferably surrounded by soft siliconeexterior shell102, permitting a good grip while scanningdevice101 across a target region, or for implantation for chronic monitoring. Typically,exterior shell102 is constructed from approved Class VI biocompatible materials as recognized by the U.S. FDA or other medical device regulatory agencies. Portions ofsensor155,power source179, lightsource LED A103A andLED B103B, or other components may protrude as needed from this shell within the spirit of this invention, provided that the protruding parts themselves are biocompatible as required.
• Withindevice101,source LED103A is illustrated in its component parts. Broad spectrum white light is emitted by a high conversion-efficiency white LED105 (e.g., The LED Light, model T1-3/4-20W-a, Fallon, Nev.).Source105 is itself embedded into a plastic beam-shaping mount using opticalclear epoxy111 to allow light generated indiode105 to be collimated, thus remaining at a near-constant diameter after passing throughoptical window115A to leavedevice101. Light then is able to pass forward as shown bylight path vectors119, with at least a portion of this light optically coupled tofirst target region123A intarget125. Note that whiletarget region125 may be in some instances a living tissue, the tissue itself is not considered to be a claimed part of this invention.
• A portion of thelight reaching region123A oftarget125 is backscattered and returns as todevice101, as shown bylight path vectors128, tooptical collection window141.Collection window141 in this embodiment is a glass, plastic, or quartz window, but can alternatively be merely an aperture, or even be a lens, as required. Light then strikessensor155, where it is sensed and detected.
• Similarly, withindevice101, there is a second light source,LED103B is illustrated in its component parts, constructed in much the same manner asLED103A, however light this time exits byoptical window115B, to strikesecond target region123B intarget125. Again, a portion of thelight reaching region123B is backscattered and returns todevice101 vialight path vector128, tooptical collection window141,striking sensor155.
• Sensor155 may be comprised of a number of discrete detectors configured to be wavelength-sensitive, or may be a continuous CCD spectrometer, with entry of light by wavelength controlled by gratings, filters, or wavelength-specific optical fibers. In any event,sensor155 transmits an ischemia signal related to the detected light backscattered fromtarget125, producing an electrical signal sent viawires161 and163 to the unit that determines a weighted difference,difference unit167.
• Light source103A and103B could be instead multiple, with up to N light sources, constructed as described, or in a varying manner. In any event,Light source103A and103B also has twoelectrical connections175 and176, connectinglight sources103A and103B topower source179. In this embodiment,power source179 is an inductive power supply, capable of receiving an inductive field from externally powered coil and RFID receiver. Such coils and receivers are well known.
• Operation of the device may now be described.
• Device101 is scanned across a breast, for example in a patient being screened for breast cancer. The device may measure the various components of the breast such as lipid and water, and/or it may measure tissue hemoglobin saturation. It may be placed on the breast directly, or it can be placed at a distance. In the latter case,vectors119 are fiber optics extended fromdevice101 and into close proximity to the target heart muscle, sufficient for optical coupling. Then the patient is allowed to heal after surgery, and the implantable device is left inside the patient's body, without a direct physical connection to the outside world.
• In this example,device101 is normally powered down and in a resting (off) state. At some point, it is desired to test the target heart muscle for the presence ofischemia. Power source179 located withindevice101, produces sufficient power fordevice101 to power up and turn on.Light sources103A,103B, and others if present, begin to illuminate thetarget125, in this case heart muscle.Sensor155, which is an embedded spectrophotometer, receives backscattered light, resolves the incoming light by wavelength, a marker of ischemia. Under control oflines175 and176,LED103A is first scanned, with an estimated tissue saturation (as determined by tissue oximeters arranged as known in the art, for example, the commercially available T-Stat model 303 Tissue Oximeter may be used, whose design and methods are incorporated into this specification by reference) of 72%. Next, under control oflines175 and176,LED103B is illuminated, producing an estimated tissue saturation of 72%. There values are sent todifference Unit167, and the difference is found to be zero, which is the median value one expects in normal tissue without cancer.
• Once the measurement is completed,device101 powers down and returns to a resting state.
• In an alternative embodiment,power source179 may be charged during proximity to external coil, or have an internal battery source, allowingdevice101 to operate whenexternal coil179 is not present.Difference unit167 may then transmit without being directly queried, such as in response to a dangerous level of ischemia.
• The breadth of uses and the basis of the present invention is best understood by example, and thus the detailed description will be further illustrated by the following examples. These examples are by no means intended to be inclusive of all uses and applications of the apparatus, merely to serve as a case study by which a person, skilled in the art, can better appreciate the methods of utilizing, and the scope of, such a device.
Example 1Simultaneous Two-Site Two-Organ Somatic Difference Monitoring
• In this example, a clinical application related to ischemia is described. Here, a surgeon is repairing the aorta. There are several reasons why the local tissue oxygenation may fall. For example, the patient is under anesthesia, and a general depression (reduction) of cardiac output may occur. If so, the delivery of oxygen to all parts of the body will fall. On the other hand, if the blood vessel supplying the colon, which arises in part from the aorta, is occluded, then the saturation to the colon will fall, but not the saturation to the cheek. Therefore, by looking at the saturation of both the cheek and colon at substantially the same time, or by displaying a difference between the two values, the cause of the drop in local oxygenation may be determined to be either local and due to the vascular repair (e.g., large difference, in this case the absolute value of |Δ saturation|>10%) which is an indication of local ischemia, or systemic and due to hypotension or cardiac failure (e.g., small difference, in this case the absolute value of |Δ saturation|<10%), which is an indication of systemic ischemia
• This is shown in the following table:

• TABLE 1
  The difference (Δ) between check and colon oxygenation is small
  (|<10%|) under normal conditions, and during system-wide,
  whole-body, global reductions in heart output, hematocrit, or
  oxygenation from the lungs. In contrast, a large difference between
  check and colon oxygenation (|>10%|) is a sign of disparate
  flow, and likely of local ischemia.

  			Δ
  	Cheek (Buccal)	Gut (Colon)	Cheek −	Local
  Site	Oxygenation	Oxygenation	Colon	Ischemia?
  Normal	76%	71%	+5%	No
  Low Heart Output	42%	48%	−6%	No
  Bad Colon Artery	76%	22%	+44%	YES

• A device displaying two values, simultaneously or near-simultaneously measured, as well as a difference-weighted value display, is shown inFIG. 2 according to some embodiments of the present invention. Monitor ordisplay313 has twosomatic probes183 and185 attached, each placed at difference sites. This number of probes could, for other embodiments, be any number of N probes, where N is two or more, within the spirit of the invention.Monitor313 displays the results of these two sites of measurement, as well as a veno-venous (or Δ) difference of 64%. In other embodiments, the display of N values itself allows a user to manually and directly compare the two values, adding medical value, or alternatively, only the difference-weighted value alone could be displayed, within the spirit of the invention. In view of this large, calculated veno-venous difference, alert322 is displayed to the user.
• Note that near-simultaneous display of the measurement of two or more somatic sites, in this case somatic tissue oxygenation as compared at two sites using a dual-site somatic tissue oximeter constructed in accordance with the present invention, allows either a direct, mutual comparison by an observer of these two displayed values, or a calculation or computation, and then display of, this difference-weighted value. Each of these, dual display for direct, mutual inspection, or calculation of a processed, weighted difference, can be a useful difference-weighted measurement. Further, it is noted that this difference-weighted value is inherently advantageous, adding medical value and relevance to either value taken alone and singly, such as by allowing detection of a local or regional ischemia with better precision, or faster recognition of an ischemic event, or by allowing more rapid identification of the source (cardiac/pulmonary) of the low oxygenation, among advantages illustrated herein. Other advantages, not discussed here, may be learned, and are incorporated into the broad list of medical advantages intended within the scope of the present invention. It is not intended that the medical advantages be subject to limitation by omission of such additional advantages.
Example 2Simultaneous Two-Site Single-Organ Somatic Difference Monitoring
• In the example above, two different organs were studied. In this example, the monitoring of a single organ, the breast, is described. It is toward this Example that the embodiment ofFIG. 1 is directed.
• In breast cancer, the detection of angiogenesis, the proliferation of new blood vessels, is a key feature of cancer that lets the cancer gain the ability to grow and spread. However, the background variation in blood content in the breast between women of different ages and breast composition makes the use of a single-site blood-content threshold less useful than it could otherwise be. That is, the range of normal blood content in breast tissue between different women is so large that the increase in blood due to cancer can be lost in that broad range.
• To illustrate this, consider data from women with breast cancer. By looking at the difference measurement of the oxygenation at one location on the breast as compared to another near-simultaneously or simultaneously measured point of the breast, and by displaying this difference, local tumor ischemia can be detected to be present (large local difference, in this case the absolute value of Δ saturation>10%) or not present (small difference, in this case the absolute value of Δ saturation<10%), as shown:

• TABLE 2
  The difference in oxygenation between two nearby regions of
  the human breast is small under normal circumstances. A tumor
  produces a local region of a high gradient of change in oxygenation
  (and also in deoxyhemoglobin content). This difference can
  be lost in the local variations (sites A and B, two sites
  within each region), but there is a large difference that
  is a sign of a tumor when one sensor is near the tumor, and
  the other is actually over the tumor.

  	Breast Site A	Breast Site B	Δ Site	Local
  Site	Saturation	Saturation	A − B	Ischemia?
  Normal 1	76%	74%	+2%	No
  Normal 2	71%	68%	+3%	No
  Normal 3	63%	66%	−3%	No
  Tumor 4	78%	66%	+12%	YES

• This Site A vs. Site B comparison gains utility because the local variations in oxygenation within a region (at two sites) are small, but the variations between patients is large. In Error! Reference source not found 2, the range of normals above is 15%, but by looking at differences between sites, only one patient is seen to have cancer.
Example 3Multi-Site Single-Organ Somatic Difference Monitoring
• In the above example, pairs of data were taken, one pair at a time. In this example, instead of plotting values from a single pair, embodiments of the present invention provide for plotting real time difference values from many measures at many sites.
• Again, using data from human subjects with and without breast cancer, the following table can be generated. Such differences can be found by having a difference in spatial separation at two points, as shown as the difference (delta) values at 5 sites labeled A-E on each subject, as follows:

• TABLE 3
  The Spatial difference at multiple sites by plotting differences,
  reduces the noise in breast tissue saturation, and allows
  simple detection of tumor near site C of Patient Tumor 4,
  in which the saturation difference has a negative then positive
  deflection (or vice-versa) during scanning.

  Patient	Δ Site A	Δ Site B	Δ Site C	Δ Site D	ΔSite E
  Normal
  1	2%	4%	−3%	5%	−3%
  Normal
  2	0%	−2%	3%	2%	−3%
  Normal
  3	1%	4%	−1%	−4%	−1%
  Tumor 4	−1%	−4%	−18%	13%	3%

• Alternatively, the above differences can be found by a single emitter/detector pair that is scanned over the tissue. Using a 3-D positional sensor (X-Y-Z) or 2-D surface motion sensor (such as the motion detection pad from an optical mouse, based upon a LED and CCD to detect translation across a surface), measures can be taken a multiple real-time instances during motion, and the delta value calculated from the different positions of the detector. So, at time zero there is no delta, while attime1 the delta is thetime1 value minus thetime0 value, attime2 the delta is thetime2 value minustime1, and so on.
Example 4Difference Abdominal Monitoring For Necrotizing Colitis Detection
• In this example, the monitoring of the premature newborn abdomen is described. A baseline probe is placed over another tissue, such as the buccal mucosa.
• As a probe is scanned across the abdomen of normal infants and across one with a regional portion of bowel with low oxygenation, the following table is created:

• TABLE 4
  The difference display allows the values abnormal for the oxygenation
  status to show ischemic necrotizing enterocolitis at sites C and
  D of patient Ischemia 4 to be displayed and/or detected.

  Patient	Δ Site A	Δ Site B	Δ Site C	Δ Site D	ΔSite D
  Normal
  1	−4%	3%	−3%	−6%	1%
  Normal
  2	0%	6%	2%	−4%	−2%
  Normal 3	−4%	0%	2%	3%	5%
  Ischemia 4	3%	5%	−22%	−37%	−10%

• In each of these cases, the medical accuracy and value of these measurement comes from or is enhanced by the simultaneous measurement of two or more somatic sites.
• It goes without saying that other configurations and embodiments shall fall within the spirit of the invention, provided that two or more measures in the body are provided more or less simultaneously. For example, the reverse situation, in which one or more sensors and a single light source is used is well within the spirit of the invention, as are multiple sensors and multiple sources, provided that more than one location is measured more or less contemporaneously, to allow an enhanced value from simultaneous measures.
• Last, an advantage is simply that the user can use one monitor at multiple sites, without having to purchase multiple monitors.
Example 5Single or Dual Site Arterio-Venous Difference Monitoring
• In prior examples, venous or tissue oxygenation values were compared. In this example, arterial and venous values are compared according to another aspect of the present invention.
• We have shown that the difference between a pulse oximeter and a tissue oximeter, one showing arterial and the other showing venous saturation, allows ischemia (low tissue oxygen delivery) and hypoxemia (low arterial blood saturation) be distinguished as described in more detail in co-pending parent application U.S. Ser. No. 11/451,681, the entire disclosure of which is hereby incorporated by reference. Embodiments of the present invention employ this difference arterial and venous saturation into a real-time calculation, and make it possible for real-time monitoring previously not available.
• In the table below, values of tissue and arterial values measured in animals are summarized. By making this a real-time calculation, these values could be demonstrated in real time, rather than determined after the fact, as had been performed in these earlier data:

• TABLE 5
  The difference display allows the differences, here calculated
  after the fact by separate measures, to be displayed. Values
  for Normoxia, Hypoxemic Hypoxia, and Ischemic Hypoxia (low
  flow and delivery) to be distinguished in animal and human
  models (from Benaron et al, Anesthesiology, 2004).

  	Normoxia	Hypoxemic Hypoxia	Ischemic Hypoxia
  Subject	(Δ saturation %)	(Δ saturation %)	(Δ saturation %)
  Human	21-29%	16%	51-91%
  Animal	25-28%	22-38%	66-83%

• In this example, this table can be incorporated intomonitor313 ofFIG. 2, in which the difference value of 64% is used to turn onischemic hypoxia alert322. Again, by making this a real-time calculation, these values could be demonstrated in real time, rather than determined after the fact, as had been performed in these earlier data.
• In some embodiments, a device is provided with dual somatic spectroscopic monitoring sites where light sources and sensors generate and detect light from at least two tissue target sites and are configured to emit light at selective wavelengths where the selective wavelengths are substantially transmitted through capillaries in tissue while being substantially absorbed by arterial and venous vessels in the tissue. This aspect is described in detail in co-pending U.S. patent application Ser. No. 11/451,681 filed on Jun. 12, 2006, the entire disclosure of which is hereby incorporated by reference. More specifically, in some embodiments the device of the present invention is configured to operate at a wavelength range, such as a range of 400 to 600 nm, and more specifically blue to green visible illuminating light (at around 500 nm). The inventors have discovered that this range of wavelengths penetrates larger vessels very poorly while being relatively highly transmitted by the capillaries, thus allowing sensitivity of the ischemia measurement at the two or more tissue sites to be increased. This is wavelength range is taught away from by oximetry art, which instead is focused on the advantages of near infrared light. This locally-weighted and microvascular-weighted measurements to detect ischemia in a local portion of a target tissue site may be utilized to determine the difference in measurements between two or more somatic monitoring sites. A locally-weighted measurement, as used herein, is a measurement that is weighted toward the condition of a local tissue near a sensor probe, rather than the blood flowing in the larger vessels that is not in physiological contact, e.g., capable of direct and significant oxygen exchange, with that local tissue. A microvascular-weighted measurement is a measurement that is weighted toward the smallest vessels, such as those having 20 microns or smaller, rather than to the blood flowing in the larger vessels that is not in physiologic contact with the local tissue.
• Due to the deep penetration of large vessels by infrared (and red) light, using infrared or red light to measure light transmittance and absorbance through tissue reflects a wide range of vessel sizes and results in measurements that are not substantially locally-weighted or microvascularly-weighted. In contrast, a blue-green weighted measurement penetrates larger vessels poorly but capillaries well, and does not travel to sufficient depths that would force inclusion of many large vessels. That is, using blue-green light to measure light transmittance and absorbance through tissue results in a substantially locally-weighted and microvascular-weighted measurement. This is non-obvious and counterintuitive to the prior art, which tends to teach the use of infrared light for its tissue-penetrating ability and against the use of the shallow-penetrating blue end of the visible spectrum.
• Another aspect of the arterial-venous approach is that it can be performed using the present invention, in the absence of a pulse oximeter, but with the a dual or single site multispectral or broadband tissue oximeter alone. This was first measured by one of the inventors in the present invention in the 1990's, and has now been further developed and an enabling embodiment invented using the device as disclosed in the present invention, with measurement even using a single probe over time produces multispectralpulse oximetry plethysmograph403, as reflected in data collected from a human subject inFIG. 3A. The intensity of the signal changes for a wide range of wavelengths over time, between a minimum to a maximum intensity, in a pulsatile manner. The maximum absorbance occurs during the period the tissue is most filled with blood (usually near the peak of systolic arterial blood pressure, but sometimes associated with the transmitted pressure of a ventilator breath, or other blood volume changes), which corresponds to localpulsatile absorbance maximum411. Similarly, as the tissue blood content falls, there is a minimum absorbance during the period the tissue is least filled with blood (usually near the end of the diastolic arterial blood pressure resting phase, but sometimes associated with the release of pressure of a ventilator breath, or other changes), which corresponds to localpulsatile absorbance minimum419.
• The important issues of the combined measurement of the pulse and tissue oximetry signals here are several-fold. First, by measuring both the venous and the arterial signal, the difference measurement can be obtained using a single probe, or by two tissue oximetry probes, wherein the arterial pulsations can be analyzed using conventional or proprietary pulse oximetry techniques (computer analysis of the difference signal, ratios at wavelengths, or even using self-adjusting variable-weight signal extraction technologies). Such a difference spectrum is illustrated for broadband pulse oximetry inFIG. 3B, where systolicpeak absorbance signal424 and diastolictrough absorbance signal426 can be subtracted to producedelta signal432. Delta signal432 may then be further analyzed to determine an arterial saturation estimate. Unsubtractedpeak absorbance signal424 and diastolictrough absorbance signal426 can then be analyzed (separately or as an average) to yield a conventional tissue capillary oximetry signal, as disclosed in this invention. The difference weighted measure here is then the arterial minus the venous signal, as described earlier in this example.
• The ability to generate a perfusion measurement warrants some attention here. The magnitude of variation in with time of delta signal432 (either in absolute terms, as a fraction of the total hemoglobin signal, or as a volume-corrected signal) can be used as a perfusion index. Another measure of perfusion is the A-V difference itself, which given a fixed amount of oxygen extraction by the tissue, widens as the inverse of the A-V (or pulse minus tissue) difference. For example, if the perfusion falls in half, and the arterial saturation is 100%, one would expect the tissue saturation to fall from 70% (30% difference) to 40% (60% difference, or twice 30%), in the absence of other physiological corrections. Combination of magnitude of time-varyingdelta signal432 and A-V difference measures, additionally even including other measures such as laser Doppler capillary velocity that are known in the art or correction of these signals for blood volume determined optically, could be used to generate a more accurate or robust perfusion index, all optically determined or even augmented with other flow-sensitive methods such as ultrasound Doppler.
Example 6Layer-Stripping Difference Monitoring for Colon Ischemia
• In the prior examples, oxygenation values were compared using a simple subtraction. In this example embodiments of the present invention provide an apparatus or device comprising a probe with a single light source and two detection fibers at different distances is used to monitor colon during interventional surgery. Alternatively, the apparatus may be comprised of a probe with two light sources and one detection fiber, or separate detection fibers and separate light sources. Other arrangements may be used by those of skill in the art, all of which are within the spirit of the present invention.
• When colon or intestine is joined at surgery, the joined site is called the anastomosis. Leakage at the joining site, called anastomotic leakage, occurs after surgery in 5%-14% of patients undergoing esophageal, gastric, intestinal, and colon anastomosis, typically several days to weeks after surgery. Leakage results in gut and colon contents spilling into normally sterile body cavities, and results in prolonged hospitalizations, sepsis, and death. However, it is currently not predictable at the time of surgery which patients will go on to leak, preventing additional and known steps to be taken in the operating room that could help avoid future leakage.
• A high-specificity mucosal, intraoperative ischemia detection system would permit real-time detection of patients at risk for leakage, allowing for real-time surgical attempts at correction of the problem. Leakage is, of course, multi-factorial, but the cause of a leak is frequently local ischemia caused by poor local perfusion, difficult access with insufficient “good” bowel to sew to, preexisting infection, and difficult location that leads to poor local perfusion. These each lead in turn leads to breakdown and leakage at the site of anastomosis. By identifying the subset of patients with poor perfusion and likely leak, those patients would be able to be the focus of more invasive procedures, procedures that would not be justified if used in all patients, but certainly justified in patents at high risk for leak.
• We tested the ability of this system to detect colon ischemia, and found that in open surgery, the top few millimeters oxygenate from the air, even if the gut is truly ischemic. Therefore we constructed a scanner, such as that shown inFIG. 1, in which optical illumination occurs at two difference locations, and measurement is made through one fiber. Equivalently, one light could be used, with two different measurement fibers, as shown inFIG. 4. Here,light source617 contains centrallight detection fiber623, as well as peripherallight detection fiber626.
• Using the device as constructed inFIG. 4, as attached to monitor313 ofFIG. 2, spectra were collected at two separations, and then the saturation was deduced using a standard radiological approach called layer stripping, in which the effect of the overlying layer is removed from the underlying layer. In this embodiment, monitor313 comprises a difference unit programmed with software know in the art for performing layer stripping. In this approach, it is not the saturation values that are subtracted, but rather by collecting and mathematically removing the narrowly-spaced spectrum (collected fromlight source617 and central fiber623) from the spectrum collected from the more widely spaced pair (light source617 and peripheral fiber626), a common data analysis tool called layer stripping in radiology, and then reanalyzing the remaining spectrum for oxygen saturation, deeper ischemia in the breast or other target tissue can reliably be detected, as shown:

• TABLE 6
  The difference, in this case calculated by removing the spectra
  collected from the deeper-collected spectrum, and then reanalyzing
  the values, allows the deeper oxygenation to be determined, thus
  showing tissues which may not heal in anastomosis

  	Narrow	Deep	Color	Deep
  Actual Tissue Measured	Pair Only	Pair Only	Difference	Ischemia?
  Ischemia Under	80%	40%	09%	Yes
  Oxygenated Surface
  Normal Under	45%	62%	69%	No
  Ischemic Surface
  Normal Tissue	70%	65%	63%	No
  Under Normal Mucosa

• In patients with ischemia, the surgical procedure can then be changed by this value, and conversely those with normal values may be allowed to undergo higher risk procedures. For example, if the ischemic site is the anastomosis of two regions of a colon, and the saturation is low, then the tissue should not be sewn together, as it will not heal. One may also use this approach to study the effect of surgical staples on ischemia, in order to determine that surgical staple lines are too tight to heal well.
• We have discovered a dual or multiple somatic measurement difference method that allows for more sensitive detection of local ischemia and or local cancer using oximetry measurements. As described above, in some embodiments the apparatus comprises two phosphor-coated LED's and integrated collimating optics constructed in accordance with the present invention to produce light at two or more target sites. Light backscattered by each target site is collected by the same or multiple sensors, allowing for an index or measure of ischemia to be determined, and subsequently transmitted to a comparison unit that additional compares the two results. This device has immediate application to several important problems, both medical and industrial, and thus constitutes an important advance in the art.

Claims (23)

1-23. (canceled)

24. An illuminator medical device, comprising:

a probe having a probe body;

an illuminator for emitting light; and,

an information chip integrated into the probe body and configured to retain information useful in the operation of the device.

25. The device ofclaim 24, wherein the useful information comprises any one or more of calibration parameters, a reference database, a library of characteristic discriminant features from previously identified tissues, probe identification, probe serial number, use history, calibration details, or other information useful in the operation of the illuminator device.

26. The device ofclaim 24, wherein the medical device is selected from the group of medical devices consisting of probes for medical endoscopic use, targetable injection needles, catheters, catheters with extendable needles, nibblers, devices with jaws, scissors, probes that measure colon oxygenation, probes that measure by pulse oximetry, probes that measure arterial oxygenation, probes that measure oxygen delivery to the body's core organs, probes that measure in the gastrointestinal system including the oropharynx, nasopharynx, esophagus, stomach, duodenum, ileum, colon, or other gastrointestinal tissues.

27. The device ofclaim 24, wherein the medical device is an oximeter probe configured for use in performing oxygenation measurements.

28. The device ofclaim 24, wherein the medical device is an oximeter probe configured for use in performing pulse oximetry.

29. The device ofclaim 24, wherein the medical device configured for use such inside, or in contact with, living tissue.

30. The device ofclaim 24, further incorporated into a spectrophotometer system.

31. The device ofclaim 24, wherein light from the illuminator is pulsed.

32. The device ofclaim 24, further incorporated into a system in which light from the illuminator is analyzed as time-resolved, frequency-resolved, or spatially-resolved.

33. The device ofclaim 24, wherein the illuminator is a broadband LED

34. The device ofclaim 33, wherein the broadband LED is a white LED

35. The device ofclaim 33, wherein the broadband LED emits at least a portion of an emitted light in the ultraviolet or infrared wavelength range.

36. The device ofclaim 33, wherein the broadband LED is composed of multiple light emitting elements, such as a combination of different light emitting diodes to produce a spectrum of light.

37. The device ofclaim 33, wherein the broadband LED is comprised of a combination of different light emitted diodes to produce a broadband and continuous spectrum of light.

38. The device ofclaim 36, wherein the multiple light emitting elements operate in at least one wavelength band.

39. The device ofclaim 33, wherein the broadband LED contains a blue LED and a phosphor.

40. The device ofclaim 33, wherein the illuminator operates to produce at least a portion of its illumination in the infrared spectrum.

41. The device ofclaim 33, wherein the illuminator operates to produce at least a portion of its illumination in the ultraviolet spectrum.

42. The device ofclaim 33, configured for use in the measurement of the oxygenation of hemoglobin.

43. The device ofclaim 33 wherein the illuminator is incorporated into a pulse oximeter.

44. The device ofclaim 33, wherein the illuminator is incorporated into a medical device that analyzes in vivo or ex vivo hemoglobins selected from the list of hemoglobins including methemoglobin, carboxyhemoglobin, and other hemoglobins with or without oxygen.

45. A method of tracking the use history or other information useful to the operation of a medical illuminator probe configured to emit light, comprising at least the steps of providing an information storage chip, and accessing information useful in the operation of the device from the chip before, during, or after device use.

Images